Literature DB >> 28616234

All that glitters is not gold: A case of lanthanum carbonate aspiration.

Suchitra Paranji1, Neethi Paranji1, Adam S Weltz2.   

Abstract

INTRODUCTION: Foreign body aspiration is a significant cause of morbidity and mortality in elderly hospitalized patients. These are typically small items that patients have access to, including small coins. CASE
PRESENTATION: This is a case report of a 75-year-old man recently bedridden from a large hemispheric stroke with sudden onset of hoarseness, cough and dysphagia. A chest X-ray was obtained which showed a radiopaque coin-shaped foreign body, presumably a coin in his aerodigestive tract. He was promptly taken to the endoscopy suite for upper endoscopy. During endoscopy, it was determined that the foreign body was a radiopaque medication that he had been given. It was easily and safely able to be crushed and lavaged down into his stomach and later determined to be lanthanum carbonate, a commonly used phosphate binder. Following endoscopy, the patient's cough, hoarseness and dysphagia resolved with no long-term complications. DISCUSSION: Lanthanum carbonate is a phosphate-binding medication used in the management and treatment of hyperphosphatemia commonly seen in patients with end-stage renal disease, which is radiopaque. There are few published reports and images of radiopaque fragments of medication in the gastrointestinal tract but none causing aspiration by masquerading as a coin-like density in the aerodigestive tract as we present here.

Entities:  

Keywords:  Gastroenterology/hepatology; neurology; pharmacoepidemiology/drug safety

Year:  2017        PMID: 28616234      PMCID: PMC5459346          DOI: 10.1177/2050313X17712642

Source DB:  PubMed          Journal:  SAGE Open Med Case Rep        ISSN: 2050-313X


Introduction

Aspiration is a major risk to elderly and debilitated patients in the hospital setting and accounts for a significant cause of morbidity and mortality. Foreign body aspiration is most commonly seen in the pediatric population under 3 years of age,[1] but adult patients with various psychiatric and neurologic conditions such as stroke are at an increased risk.[2]

Case presentation

Our patient is a 75-year-old man with a history of stage 5 chronic kidney disease, hypertension and pre-diabetes. He was recently bedridden from a large hemispheric stroke and hospitalized at a large rural center for ongoing care. He was discovered during morning rounds to have had sudden onset of hoarseness, cough and dysphagia. On physical examination, his vital signs were within normal limits; however, he appears to be in a mild amount of distress. A chest X-ray was obtained (Figure 1) which showed a radiopaque coin-shaped foreign body, presumably a coin in his posterior oropharynx. This was unable to be fully evaluated and addressed at the bedside, as the object could not be seen on visual inspection. An additional lateral chest X-ray (Figure 2) was obtained and the patient was taken promptly for upper endoscopy. During endoscopy, it was determined that the foreign body was a pill (Figure 3) that he had been given that morning. The pill was easily and safely able to be crushed and lavaged down into his stomach. Upon review of his recent medications, the pill was determined to be lanthanum carbonate (LC), a phosphate binder used in the management and treatment of hyperphosphatemia in patients with chronic kidney disease. Following endoscopy, the patient’s cough, hoarseness and dysphagia resolved with no long-term complications. The patient was eventually discharged to rehab with no long-term sequela of this event.
Figure 1.

AP chest xray showing coin-shaped foreign body.

Figure 2.

Lateral neck xray depicting coin-shaped foreign body.

Figure 3.

Endoscopic view of foreign body in oropharynx.

AP chest xray showing coin-shaped foreign body. Lateral neck xray depicting coin-shaped foreign body. Endoscopic view of foreign body in oropharynx.

Discussion

LC is a non-aluminum non-calcium phosphate-binding medication that is very commonly used to help lower serum phosphate levels in patients with advanced renal disease.[3] It is sold under the trade name Fosrenol by the pharmaceutical company Shire Pharmaceuticals. LC has been indicated for the management of hyperphosphatemia in patients with end-stage renal disease (ESRD) in the United States since 2005.[4] Several observational studies have shown that the treatment of hyperphosphatemia with phosphate-binding agents reduces the risk of mortality compared with no treatment in patients with ESRD.[5-8] Because of this, clinicians often prescribe these medications to patients and like many medications may not pay much attention to specific features such as size or texture of the pill or tablet. Due to the large size of LC (1000 mg tablet is 2.2 cm in diameter), it may be possible to choke on the tablet if it is not properly chewed or crushed. There are also possible risks associated with build-up of aluminum-like particles and long-term toxicity that are beyond the scope of this article, reported in the literature.[3] This medication has recently been found to be radiopaque on advanced forms of imaging within the gastrointestinal tract.[9,10] There is a dearth of published literature discussing the topic of aspiration of radiopaque medications; however, recent published reports of LC fragments causing artifact on computed tomography causing diagnostic confusion, being indistinguishable from foreign bodies, has been reported.[9]

Conclusion

Large pills are often difficult for elderly patients to swallow, particularly those with a history of stroke or other neurocognitive disorders. The differential diagnosis for aspiration is often broad and should not only include a history and physical examination, but a detailed review and knowledge of a patient’s medication list. Not all coin-like densities on imaging are coins. LC is not only radiopaque but should be crushed prior to being given according to its package insert. Failure to do so and without prompt diagnosis and intervention can lead to significant morbidity and possibly even mortality.
  10 in total

Review 1.  Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.

Authors:  F Albaaj; A J Hutchison
Journal:  Int J Clin Pract       Date:  2005-09       Impact factor: 2.503

Review 2.  Foreign Body Inhalation in the Adult Population: Experience of 25,998 Bronchoscopies and Systematic Review of the Literature.

Authors:  Inderpaul Singh Sehgal; Sahajal Dhooria; Babu Ram; Navneet Singh; Ashutosh N Aggarwal; Dheeraj Gupta; Digambar Behera; Ritesh Agarwal
Journal:  Respir Care       Date:  2015-05-12       Impact factor: 2.258

3.  Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status.

Authors:  Antonio Alberto Lopes; Lin Tong; Jyothi Thumma; Yun Li; Douglas S Fuller; Hal Morgenstern; Jürgen Bommer; Peter G Kerr; Francesca Tentori; Takashi Akiba; Brenda W Gillespie; Bruce M Robinson; Friedrich K Port; Ronald L Pisoni
Journal:  Am J Kidney Dis       Date:  2012-03-03       Impact factor: 8.860

4.  [Lanthanum carbonate abdominal foreign bodies].

Authors:  Iago Pinal Fernández; María Morís Felgueroso; Ernesto Trallero Araguás
Journal:  Med Clin (Barc)       Date:  2014-01-28       Impact factor: 1.725

Review 5.  Airway foreign bodies: A critical review for a common pediatric emergency.

Authors:  Alaaddin M Salih; Musab Alfaki; Dafalla M Alam-Elhuda
Journal:  World J Emerg Med       Date:  2016

6.  Use of phosphate-binding agents is associated with a lower risk of mortality.

Authors:  Jorge B Cannata-Andía; José L Fernández-Martín; Francesco Locatelli; Gérard London; José L Gorriz; Jürgen Floege; Markus Ketteler; Aníbal Ferreira; Adrian Covic; Boleslaw Rutkowski; Dimitrios Memmos; Willem-Jan Bos; Vladimir Teplan; Judit Nagy; Christian Tielemans; Dierik Verbeelen; David Goldsmith; Reinhard Kramar; Pierre-Yves Martin; Rudolf P Wüthrich; Drasko Pavlovic; Miha Benedik; José Emilio Sánchez; Pablo Martínez-Camblor; Manuel Naves-Díaz; Juan J Carrero; Carmine Zoccali
Journal:  Kidney Int       Date:  2013-07-03       Impact factor: 10.612

7.  Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia.

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Hajime Suzuki; Miho Hida; Takao Suga; Masafumi Fukagawa
Journal:  Nephrol Dial Transplant       Date:  2014-11-23       Impact factor: 5.992

8.  Beam-hardening artifacts on computed tomography images caused by lanthanum carbonate hydrate in a patient on dialysis.

Authors:  Hiromitsu Hayashi; Minoru Machida; Tetsuro Sekine; Hidenori Yamaguchi; Tomonari Kiriyama; Shin-Ichiro Kumita
Journal:  Jpn J Radiol       Date:  2010-05-29       Impact factor: 2.374

9.  Phosphorus binders and survival on hemodialysis.

Authors:  Tamara Isakova; Orlando M Gutiérrez; Yuchiao Chang; Anand Shah; Hector Tamez; Kelsey Smith; Ravi Thadhani; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

Review 10.  Lanthanum carbonate: safety data after 10 years.

Authors:  Alastair J Hutchison; Rosamund J Wilson; Svetlana Garafola; John Brian Copley
Journal:  Nephrology (Carlton)       Date:  2016-12       Impact factor: 2.506

  10 in total
  2 in total

1.  Lanthanum-Induced Radiopaque Intestinal Precipitates: A Potential Cause of Intestinal Foreign Bodies.

Authors:  Jason Galo; Bianca Madrid; Warren Kupin
Journal:  Case Rep Nephrol       Date:  2019-09-02

Review 2.  Lanthanum Carbonate Opacities-A Systematic Review.

Authors:  Jan Kampmann; Nina Pirschel Hansen; Anders Nikolai Ørsted Schultz; Andreas Hjelm Brandt; Frans Brandt
Journal:  Diagnostics (Basel)       Date:  2022-02-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.